We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Magnolia Compound Is a Potent Anti-Cancer Agent

By Biotechdaily staff writers
Posted on 22 Jul 2008
Cancer researchers have shown that honokiol, a compound isolated from magnolia suppresses tumor growth by inhibiting the activity of the enzyme phospholipase D (PLD).

Honokiol is a biphenolic molecule present in the cones, bark, and leaves of Magnolia grandiflora that has been used in traditional Japanese medicine as an anxiolytic, anti-thrombotic, anti-depressant, anti-emetic, and anti-bacterial. While early research on the effective compounds in traditional remedies simply used whole magnolia bark extracts, known as houpu magnolia, more recent work has identified honokiol and its structural isomer magnolol as the active compounds in magnolia bark.

Elevated phospholipase D (PLD) activity provides a survival signal in several human cancer cell lines and suppresses apoptosis when cells are subjected to the stress of serum withdrawal. The tumor promoting effects of PLD are lined to the activity of RAS, which drives molecular pumps that remove chemotherapy drugs from cancer cells.

Investigators at the Emory University School of Medicine (Atlanta, GA, USA) used human cell lines growing in culture to evaluate the dependence of PLD survival signals on Ras and the effect of honokiol on Ras activation.

Results published in the July 2008 issue of the journal Clinical Cancer Research revealed that PLD activity was commonly elevated in response to the stress of serum withdrawal, and that the stress-induced increase in PLD activity was selectively suppressed by honokiol. The stress-induced increase in PLD activity was accompanied by increased Ras activation, and the stress-induced increase in PLD activity in MDA-MB-231 breast cancer cells was dependent on a Ras. These results allowed the authors to conclude that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.

"Knowing more about how honokiol works will tell us what kinds of cancer to go after,” said senior author Dr. Jack Arbiser, associate professor of dermatology at Emory University School of Medicine. "We found that it is particularly potent against tumors with activated Ras. Honokiol could be effective as a way to make tumors more sensitive to traditional chemotherapy.”


Related Links:
Emory University School of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
POC Immunoassay Analyzer
Procise DX

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
22 Jul 2008  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
22 Jul 2008  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
22 Jul 2008  |   BioResearch